Yousif Capital Management LLC Invests $3.56 Million in NeoGenomics, Inc. (NASDAQ:NEO) – Watch List News
Other institutional investors have also recently made changes to their positions in the company. Destiny Wealth Partners LLC purchased a new stake in NeoGenomics during the third quarter valued at approximately $65,000. Archer Investment Corp raised its position in NeoGenomics by 37.1% during the third quarter. Archer Investment Corp now owns 1,350 shares of the medical research company’s stock valued at $65,000 after purchasing an additional 365 shares during the period. James Investment Research Inc. raised its position in NeoGenomics by 47.5% during the third quarter. James Investment Research Inc. now owns 1,550 shares of the medical research company’s stock valued at $75,000 after purchasing an additional 499 shares during the period. Lindbrook Capital LLC purchased a new stake in NeoGenomics during the fourth quarter valued at approximately $84,000. Finally, Andrew Hill Investment Advisors Inc. purchased a new stake in NeoGenomics during the fourth quarter valued at approximately $88,000. 97.04% of the stock is owned by institutional investors.
Several equities research analysts have recently weighed in on the company. SVB Leerink reduced their price target on NeoGenomics from $45.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, March 29th. Morgan Stanley reduced their price target on NeoGenomics from $30.00 to $29.00 and set an “equal weight” rating on the stock in a report on Thursday, February 24th. StockNews.com assumed coverage on NeoGenomics in a report on Thursday, March 31st. They set a “sell” rating on the stock. Cowen reduced their price objective on NeoGenomics from $42.00 to $24.00 and set an “outperform” rating on the stock in a report on Tuesday, March 29th. Finally, Needham & Company LLC reduced their price objective on NeoGenomics from $29.00 to $19.00 and set a “buy” rating on the stock in a report on Tuesday, March 29th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $25.36.
NEO opened at $13.97 on Friday. The firm has a market capitalization of $1.73 billion, a PE ratio of -126.99 and a beta of 0.74. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.81 and a quick ratio of 7.54. The business’s 50-day moving average is $18.43 and its two-hundred day moving average is $30.51. NeoGenomics, Inc. has a 1 year low of $11.00 and a 1 year high of $54.74.
NeoGenomics (NASDAQ:NEO – Get Rating) last released its quarterly earnings results on Wednesday, February 23rd. The medical research company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.03. The business had revenue of $125.73 million during the quarter, compared to analyst estimates of $125.77 million. NeoGenomics had a negative net margin of 1.72% and a negative return on equity of 4.17%. The company’s quarterly revenue was down .2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.12 earnings per share. As a group, sell-side analysts expect that NeoGenomics, Inc. will post -0.75 EPS for the current year.
In other NeoGenomics news, CFO William Bonello sold 3,209 shares of the stock in a transaction dated Monday, March 7th. The shares were sold at an average price of $18.29, for a total transaction of $58,692.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.70% of the company’s stock.
NeoGenomics Profile (Get Rating)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
See Also
- Get a free copy of the StockNews.com research report on NeoGenomics (NEO)
- 4 Sin Stocks to Give Your Portfolio a Shot in the Arm
- 3 Dividend Growth Stocks to Help You Fight Inflation
- MarketBeat Podcast: Buy, Sell or Hold – Nike, Nio and Starbucks
- Lamb Weston Is One Hot Potato
- Inflation Drags On Conagra Brands Results
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source